Pfizer's $11 billion buyback plan deflates AstraZeneca bid hopes
October 24, 2014 at 04:11 AM EDT
LONDON/NEW YORK (Reuters) - U.S. drugmaker Pfizer is to continue buying back stock, with the board authorizing a new $11 billion share repurchase plan, deflating expectations that it will make a new bid for AstraZeneca.
